313 related articles for article (PubMed ID: 30370487)
1. Update on Therapeutic Options in Lipodystrophy.
Akinci B; Meral R; Oral EA
Curr Diab Rep; 2018 Oct; 18(12):139. PubMed ID: 30370487
[TBL] [Abstract][Full Text] [Related]
2. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
Akinci G; Akinci B
Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
[TBL] [Abstract][Full Text] [Related]
3. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
Tchang BG; Shukla AP; Aronne LJ
Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
[TBL] [Abstract][Full Text] [Related]
4. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
[TBL] [Abstract][Full Text] [Related]
5. Treatment Options for Lipodystrophy in Children.
Mainieri F; Tagi VM; Chiarelli F
Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578
[TBL] [Abstract][Full Text] [Related]
6. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
[TBL] [Abstract][Full Text] [Related]
7. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ
Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105
[TBL] [Abstract][Full Text] [Related]
9. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
10. Leptin replacement therapy in the management of lipodystrophy syndromes.
Vigouroux C; Mosbah H; Vatier C
Ann Endocrinol (Paris); 2024 Jun; 85(3):201-204. PubMed ID: 38871500
[TBL] [Abstract][Full Text] [Related]
11. Metreleptin: first global approval.
Chou K; Perry CM
Drugs; 2013 Jun; 73(9):989-97. PubMed ID: 23740412
[TBL] [Abstract][Full Text] [Related]
12. Metreleptin treatment of non-HIV lipodystrophy syndromes.
Chevalier B; Lemaitre M; Leguier L; Mapihan KL; Douillard C; Jannin A; Espiard S; Vantyghem MC
Presse Med; 2021 Nov; 50(3):104070. PubMed ID: 34571177
[TBL] [Abstract][Full Text] [Related]
13. Rationale for leptin-replacement therapy for severe lipodystrophy.
Oral EA; Chan JL
Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299
[TBL] [Abstract][Full Text] [Related]
14. Lymphoma in acquired generalized lipodystrophy.
Brown RJ; Chan JL; Jaffe ES; Cochran E; DePaoli AM; Gautier JF; Goujard C; Vigouroux C; Gorden P
Leuk Lymphoma; 2016; 57(1):45-50. PubMed ID: 25864863
[TBL] [Abstract][Full Text] [Related]
15. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
Miehle K; Stumvoll M; Fasshauer M; Hierl T
Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984
[TBL] [Abstract][Full Text] [Related]
16. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
[TBL] [Abstract][Full Text] [Related]
17. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.
Lebastchi J; Ajluni N; Neidert A; Oral EA
J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101
[TBL] [Abstract][Full Text] [Related]
18. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
[TBL] [Abstract][Full Text] [Related]
20. New advances in the treatment of generalized lipodystrophy: role of metreleptin.
Rodriguez AJ; Mastronardi CA; Paz-Filho GJ
Ther Clin Risk Manag; 2015; 11():1391-400. PubMed ID: 26396524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
